Pulse Biosciences, Inc. (PLSE)Healthcare | Medical Instruments & Supplies | Miami, United States | NasdaqCM
25.89 USD
-0.40
(-1.522%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 25.89 |
Hot Take ↕ | July 11, 2026, 3:47 a.m. EDT
The long-term investment case is fundamentally broken. Despite a headline-grabbing 256% cumulative gain over the last nine years, the company is currently generating negative gross margins (-21%), negative operating cash flow, and trading at a price-to-book ratio of 27x while reporting losses. The market has priced in a complete failure of the business model, as indicated by the negative forward P/E and the fact that the trailing twelve-month EPS is -$1.10. The recent price surge is a classic 'value trap' reversal fueled by speculative news cycles rather than operational improvement; the stock is up significantly on paper, but the underlying economics remain deeply distressed. In the short term, the technicals show a fragile uptrend off the lows, yet the options market screams caution. Traders are buying deep protection, creating a heavy overhang that could trigger a sharp correction if sentiment wavers. The statistical forecasting model offers no directional guidance, reflecting the chaotic nature of the price action. While the stock has rallied recently, the disconnect between the deteriorating fundamentals and the price action makes this a high-risk speculative play rather than a sound investment opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.142406 |
| AutoTheta | 0.153642 |
| AutoARIMA | 0.153923 |
| AutoETS | 0.153924 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.047 |
| Excess Kurtosis | -0.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.792 |
| Revenue per Share | 0.011 |
| Market Cap | 1,791,839,360 |
| Forward P/E | -23.75 |
| Beta | 1.65 |
| Website | https://www.pulsebiosciences.com |
As of July 11, 2026, 3:47 a.m. EDT: Speculators are aggressively positioning for a crash, evidenced by massive put volume and open interest at deep out-of-the-money strikes ($3.00) with extreme implied volatility spikes. Conversely, call activity is concentrated at very high strikes ($35.00-$40.00) with negligible volume, indicating a lack of genuine bullish conviction. The skew suggests a 'bearish gamma' environment where traders are hedging against downside risk rather than betting on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6359676 |
| Address1 | 601 Brickell Key Drive |
| Address2 | Suite 1080 |
| All Time High | 45.82 |
| All Time Low | 1.18 |
| Ask | 32.92 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 447,230 |
| Average Daily Volume3 Month | 342,127 |
| Average Volume | 342,127 |
| Average Volume10Days | 447,230 |
| Beta | 1.647 |
| Bid | 19.13 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.972 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.89 |
| Current Ratio | 7.261 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 26.7 |
| Day Low | 25.42 |
| Debt To Equity | 10.792 |
| Display Name | Pulse Biosciences |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,777,897,800 |
| Earnings Timestamp End | 1,777,897,800 |
| Earnings Timestamp Start | 1,777,897,800 |
| Ebitda | -76,402,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.652 |
| Enterprise To Revenue | 2,304.495 |
| Enterprise Value | 1,730,675,456 |
| Eps Current Year | -1.07 |
| Eps Forward | -1.09 |
| Eps Trailing Twelve Months | -1.1 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.9395 |
| Fifty Day Average Change | 0.9504986 |
| Fifty Day Average Change Percent | 0.038112175 |
| Fifty Two Week Change Percent | 63.59676 |
| Fifty Two Week High | 31.0 |
| Fifty Two Week High Change | -5.1100006 |
| Fifty Two Week High Change Percent | -0.16483873 |
| Fifty Two Week Low | 12.56 |
| Fifty Two Week Low Change | 13.329999 |
| Fifty Two Week Low Change Percent | 1.0613056 |
| Fifty Two Week Range | 12.56 - 31.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,463,578,200,000 |
| Float Shares | 18,476,917 |
| Forward Eps | -1.09 |
| Forward P E | -23.752293 |
| Free Cashflow | -29,080,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 116 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -0.21039 |
| Gross Profits | -158,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.73210996 |
| Held Percent Institutions | 0.11587 |
| Implied Shares Outstanding | 69,209,712 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida. |
| Long Name | Pulse Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,791,839,360 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_276735354 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -74,567,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,820,907,522 |
| Number Of Analyst Opinions | 3 |
| Open | 25.9 |
| Operating Cashflow | -55,196,000 |
| Operating Margins | -47.75561 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 510 906 4600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 25.89 |
| Post Market Time | 1,783,981,118 |
| Previous Close | 26.29 |
| Price Eps Current Year | -24.19626 |
| Price Hint | 2 |
| Price To Book | 26.635801 |
| Price To Sales Trailing12 Months | 2,385.938 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.99 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.400002 |
| Regular Market Change Percent | -1.5215 |
| Regular Market Day High | 26.7 |
| Regular Market Day Low | 25.42 |
| Regular Market Day Range | 25.42 - 26.7 |
| Regular Market Open | 25.9 |
| Regular Market Previous Close | 26.29 |
| Regular Market Price | 25.89 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 209,637 |
| Return On Assets | -0.45025003 |
| Return On Equity | -0.80722 |
| Revenue Per Share | 0.011 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 69,209,712 |
| Shares Percent Shares Out | 0.041300002 |
| Shares Short | 2,856,310 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,086,437 |
| Short Name | Pulse Biosciences, Inc |
| Short Percent Of Float | 0.1486 |
| Short Ratio | 7.5 |
| Source Interval | 15 |
| State | FL |
| Symbol | PLSE |
| Target High Price | 32.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 30.66667 |
| Target Median Price | 30.0 |
| Total Cash | 68,319,000 |
| Total Cash Per Share | 0.987 |
| Total Debt | 7,155,000 |
| Total Revenue | 751,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.441525 |
| Two Hundred Day Average Change | 6.448475 |
| Two Hundred Day Average Change Percent | 0.33168566 |
| Type Disp | Equity |
| Volume | 209,637 |
| Website | https://www.pulsebiosciences.com |
| Zip | 33,131 |